Delving into the Latest Updates on BW-20805 with Synapse

Overview

Basic Info

Drug Type

siRNA

Synonyms

Target

KLKB1

Mechanism

KLKB1 inhibitors(Plasma kallikrein inhibitors)

Therapeutic Areas

Immune System DiseasesCardiovascular DiseasesCongenital Disorders+ [2]

Active Indication

Hereditary Angioedema

Inactive Indication-

Originator Organization

Hangzhou Bolin Pharmaceutical Technology Co., Ltd.

Active Organization

Hangzhou Bolin Pharmaceutical Technology Co., Ltd.ARGO BIOPHARMA AUSTRALIA PTY LTD

Inactive Organization-

Drug Highest PhasePhase 2

First Approval Date-

Regulation-

Login to view timeline

Structure/Sequence

Boost your research with our RNA technology data.

login

or

view full example data

Boost your research with our RNA technology data.

主要目的：评估BW-20805在健康受试者中单剂给药的安全性和耐受性。次要目的：评估BW-20805及其代谢物（如有）在健康受试者中单剂给药的药代动力学（PK）特征；评估BW-20805及其代谢物（如有）在健康受试者中单剂给药的药效学（PD）特征。

[Translation]

Primary objective: To evaluate the safety and tolerability of a single dose of BW-20805 in healthy subjects. Secondary objective: To evaluate the pharmacokinetic (PK) characteristics of a single dose of BW-20805 and its metabolites (if any) in healthy subjects; To evaluate the pharmacodynamic (PD) characteristics of a single dose of BW-20805 and its metabolites (if any) in healthy subjects.

Start Date06 Nov 2023

Sponsor / Collaborator

Hangzhou Bolin Pharmaceutical Technology Co., Ltd.

ACTRN12623000689673

/ RecruitingPhase 1

A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Subcutaneously Administered BW-20805 in Healthy Subjects

Start Date04 Aug 2023

Sponsor / Collaborator

ARGO BIOPHARMA AUSTRALIA PTY LTD

100 Clinical Results associated with BW-20805

Login to view more data

100 Translational Medicine associated with BW-20805

Login to view more data

100 Patents (Medical) associated with BW-20805

Login to view more data

100 Deals associated with BW-20805

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hereditary Angioedema	Phase 2	CN	Hangzhou Bolin Pharmaceutical Technology Co., Ltd.	13 Jan 2025
Hereditary Angioedema	Phase 2	ES	Hangzhou Bolin Pharmaceutical Technology Co., Ltd.	13 Jan 2025
Hereditary Angioedema	Phase 2	US	Hangzhou Bolin Pharmaceutical Technology Co., Ltd.	13 Jan 2025
Hereditary Angioedema	Phase 2	IT	Hangzhou Bolin Pharmaceutical Technology Co., Ltd.	13 Jan 2025
Hereditary Angioedema	Phase 2	DE	Hangzhou Bolin Pharmaceutical Technology Co., Ltd.	13 Jan 2025
Hereditary Angioedema	Phase 2	PL	Hangzhou Bolin Pharmaceutical Technology Co., Ltd.	13 Jan 2025